Difference between revisions of "Anagrelide (Agrylin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| Line 10: | Line 10: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Essential thrombocythemia]] | *[[Essential thrombocythemia]] | ||
| + | *[[Polycythemia vera]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 27: | Line 28: | ||
[[Category:Essential thrombocythemia medications]] | [[Category:Essential thrombocythemia medications]] | ||
| + | [[Category:Polycythemia vera medications]] | ||
[[Category:FDA approved in 1997]] | [[Category:FDA approved in 1997]] | ||
Revision as of 18:00, 23 August 2018
General information
Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.[1][2]
Route: PO
Extravasation: n/a
- Example of usage: Anagrelide (Agrylin) 0.5 mg PO 4 times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Anagrelide (Agrylin) patient drug information (Chemocare)[3]
- Anagrelide (Agrylin) patient drug information (UpToDate)[4]
Also known as
- Brand names: Agrylin, Xagrid